Clinical Trial Update: Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial comparing ANF-RHO to Neulasta for chemotherapy-induced neutropenia has been terminated. The study was a dose-finding assessment of ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia

Drugs mentioned

• ANF-RHO
• NEULASTA (pegfilgrastim)

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Chemotherapy-induced Neutropenia | Phase 2 | Status: TERMINATED